Charles Rhyee
Stock Analyst at TD Cowen
(2.23)
# 2,766
Out of 5,152 analysts
75
Total ratings
50%
Success rate
-5.21%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Hold | $8 → $6 | $5.10 | +17.76% | 7 | Feb 26, 2026 | |
| CRL Charles River Laboratories International | Maintains: Buy | $251 → $235 | $179.35 | +31.03% | 7 | Feb 20, 2026 | |
| TALK Talkspace | Maintains: Buy | $6 → $9 | $4.77 | +88.68% | 3 | Feb 20, 2026 | |
| ICLR ICON Public Limited Company | Upgrades: Buy | $183 → $120 | $110.17 | +8.93% | 7 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Upgrades: Hold | $462 → $419 | $465.30 | -9.95% | 7 | Feb 18, 2026 | |
| CI The Cigna Group | Maintains: Buy | $333 → $338 | $281.61 | +20.02% | 2 | Feb 9, 2026 | |
| MCK McKesson | Maintains: Buy | $1,000 → $1,012 | $930.40 | +8.77% | 5 | Feb 5, 2026 | |
| IQV IQVIA Holdings | Maintains: Hold | $215 → $245 | $177.13 | +38.32% | 3 | Jan 22, 2026 | |
| FTRE Fortrea Holdings | Maintains: Hold | $7 → $15 | $9.85 | +52.28% | 4 | Jan 22, 2026 | |
| MDLN Medline | Initiates: Buy | $46 | $43.24 | +6.38% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.29 | +162.58% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $400 | $353.75 | +13.07% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $100 | $79.06 | +26.49% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $183 → $225 | $217.55 | +3.42% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $27 | $31.01 | -12.93% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $297 → $380 | $192.44 | +97.46% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $5.80 | +762.07% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $11.86 | +372.18% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $9.64 | +2,805.20% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $3.27 | +1,429.05% | 2 | Jun 21, 2022 |
Teladoc Health
Feb 26, 2026
Maintains: Hold
Price Target: $8 → $6
Current: $5.10
Upside: +17.76%
Charles River Laboratories International
Feb 20, 2026
Maintains: Buy
Price Target: $251 → $235
Current: $179.35
Upside: +31.03%
Talkspace
Feb 20, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $4.77
Upside: +88.68%
ICON Public Limited Company
Feb 18, 2026
Upgrades: Buy
Price Target: $183 → $120
Current: $110.17
Upside: +8.93%
Medpace Holdings
Feb 18, 2026
Upgrades: Hold
Price Target: $462 → $419
Current: $465.30
Upside: -9.95%
The Cigna Group
Feb 9, 2026
Maintains: Buy
Price Target: $333 → $338
Current: $281.61
Upside: +20.02%
McKesson
Feb 5, 2026
Maintains: Buy
Price Target: $1,000 → $1,012
Current: $930.40
Upside: +8.77%
IQVIA Holdings
Jan 22, 2026
Maintains: Hold
Price Target: $215 → $245
Current: $177.13
Upside: +38.32%
Fortrea Holdings
Jan 22, 2026
Maintains: Hold
Price Target: $7 → $15
Current: $9.85
Upside: +52.28%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $46
Current: $43.24
Upside: +6.38%
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.29
Upside: +162.58%
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $353.75
Upside: +13.07%
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $79.06
Upside: +26.49%
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $217.55
Upside: +3.42%
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $31.01
Upside: -12.93%
Oct 7, 2025
Upgrades: Buy
Price Target: $297 → $380
Current: $192.44
Upside: +97.46%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $5.80
Upside: +762.07%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $11.86
Upside: +372.18%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $9.64
Upside: +2,805.20%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $3.27
Upside: +1,429.05%